H.C. Wainwright lowered the firm’s price target on ImmunoPrecise Antibodies (IPA) to $5 from $7 and keeps a Buy rating on the shares. The firm cites stock dilution for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPA:
- ImmunoPrecise Antibodies Reports Q3 FY25 Financial Results
- ImmunoPrecise Antibodies Announces Strategic Partnership and AI Expansion
- ImmunoPrecise Antibodies reports Q3 EPS (C$0.66) vs. (C$0.10) last year
- Options Volatility and Implied Earnings Moves Today, March 28, 2025
- IPA Earnings Report this Week: Is It a Buy, Ahead of Earnings?